1. Introduction {#sec1}
===============

Multiple system atrophy (MSA) is a progressive neurodegenerative movement disorder characterized by autonomic failure, poorly levodopa-responsive parkinsonism, cerebellar ataxia, and pyramidal symptoms in variable combinations. Neuronal cell loss in the basal ganglia, cerebellum, pontine and inferior olivary nuclei, pyramidal tract, intermediolateral cell column, and Onuf\'s nucleus as well as gliosis are typically observed ([@bib90]). MSA is commonly regarded as a primary oligodendrogliopathy ([@bib91]) because of widespread glial cytoplasmic inclusions (GCIs; Papp-Lantos bodies) that are seen even in brain areas without evident neuronal loss. GCIs were first identified in 1989 using Gallyas silver impregnation ([@bib23; @bib60]) and were later shown to be immunoreactive for α-synuclein ([@bib41; @bib88]), thereby linking MSA with other synucleinopathies, such as Parkinson\'s disease (PD) and dementia with Lewy bodies (DLB) ([@bib79]). Genetic studies have shown that variants in the *SNCA* gene, coding for α-synuclein, are major risk factors for MSA (see [section 4.1](#sec4.1){ref-type="sec"}). This recent finding represents a major breakthrough in our understanding of MSA.

Apart from the role of the *SNCA* gene, the etiopathogenesis of MSA is still enigmatic. Interactions of genetic and environmental factors, similar to other complex, sporadic neurodegenerative diseases, are likely ([@bib11]). In a few controlled studies, an increased risk of developing MSA conferred by occupational and daily habits, such as exposure to solvents, additives, plastic monomers, metals, and various other toxins ([@bib24; @bib50; @bib84]), as well as a history of farming ([@bib11; @bib87]) has been observed. A recent study, however, questioned some of these associations ([@bib87]). In general, convincing findings from environmental studies are hard to obtain due to limiting factors such as recall (overreporting of exposure) and selection bias (patients with severe diseases are less able to participate) ([@bib80]). Thus the role of environmental factors is far from clear.

A disease-causing gene has not been identified in the few postmortem proven MSA pedigrees that will be reviewed here; however, these families indicate that monogenic MSA may occur ([@bib30; @bib94]). In this article, we provide an update on genetic studies in MSA and discuss how they may increase our understanding of the pathogenesis of this devastating disorder.

2. Familial and monogenic MSA {#sec2}
=============================

Familial aggregation has been consistently documented for PD ([@bib82]) but only rare reports of familial MSA exist ([@bib30; @bib77; @bib94]). A recent study found a higher frequency of parkinsonism among first-degree relatives of MSA patients ([@bib86]). This is consistent with earlier findings reporting that 13% of MSA patients had at least 1 first-degree or second-degree relative with parkinsonism ([@bib92]) and that higher frequencies of neurological disease occur among first-degree relatives of MSA patients ([@bib50]). In contrast, a positive family history for PD has not been shown to be a risk factor for MSA ([@bib85]).

Only a few familial cases with MSA have been reported. One German family with probable MSA affecting 2 members in 2 successive generations was described ([@bib94]). Genetic testing excluded spinocerebellar ataxia (SCA) types 1--3, 6, 7, and 17 as well as mutations in the α-synuclein gene ([@bib58; @bib94]). One affected patient died subsequently and the diagnosis was confirmed according to standard neuropathological criteria ([@bib83; @bib95]).

A second family was reported in which a female patient with probable MSA had a father who was diagnosed at first with cortical cerebellar atrophy (CCA) and after developing orthostatic hypotension a few months later with probable MSA ([@bib77]). Pedigree structure in both of these families was consistent with autosomal dominant inheritance.

In 2007, 4 Japanese MSA families with multiple affected siblings were reported ([@bib30]). One patient had definite MSA, 5 patients were diagnosed with probable MSA, and the remaining 2 patients had possible MSA. Because a consanguineous marriage was noted for 1 family, both men and women were affected and because none of the affected individuals were ascertained in successive generations, an autosomal recessive mode of inheritance is likely. Mutational analysis of the coding regions of *SNCA*, however, failed to identify any mutations ([@bib30]).

*SNCA* missense and multiplication mutations are a rare cause of parkinsonism. To date only a few families have been described with duplication or triplication mutations involving this locus ([@bib21; @bib62; @bib76]). Clinical symptoms of *SNCA* multiplication patients sometimes resemble symptoms usually seen in MSA, suggesting that the clinical phenotype can be more variable and does not necessarily resemble that of idiopathic PD ([@bib21]). Furthermore, neuropathological studies in *SNCA* triplication cases demonstrated GCI-like inclusions in addition to Lewy bodies ([@bib20; @bib29; @bib49; @bib89]).

In order to shed more light on the genetic background and a possible hereditary component of MSA, it is therefore crucial to ascertain informative families for systematic genetic screening. Efforts are underway to sequence the exome, which is the entire coding sequence of the genome, in familial MSA cases in an attempt to identify disease-causing mutations.

3. Genocopies of familial MSA {#sec3}
=============================

MSA patients share some clinical features, such as prominent ataxia, dysmetria, and eye movement abnormalities, with autosomal dominant spinocerebellar ataxias (SCAs) ([@bib69]). For instance, an MSA-C-like presentation has been reported for a family with SCA1 triplet repeat expansion ([@bib26]). Neuropathological changes involved not only cerebellum and brainstem, but also basal ganglia, thalamus, and intermediolateral columns of the spinal cord; furthermore tau- and ubiquitin-positive GCIs were reported. Several features of the index patient, however, were found to be unusual for MSA including early disease onset, cerebellar and autonomic features in the absence of any pyramidal or extrapyramidal signs, as well as sparse argyrophillic inclusions positive for tau and ubiquitin. Unfortunately, α-synuclein immunostaining was unavailable at the time of the study and therefore a definitive diagnosis of MSA could not be made ([@bib41; @bib83]).

[@bib7] reported ubiquitin-positive GCIs in a patient with familial olivoponto-cerebellar atrophy (OPCA). A molecular genetic analysis in the patient\'s son showed CAG repeat expansion in the SCA2 gene. The proband\'s material was re-examined and immunohistochemistry showed ubiquitin-positive, α-synuclein-negative GCI-like inclusions ([@bib8]). Hence, in the absence of α-synuclein-positive GCIs, it is recommended to avoid the use of the term MSA to designate any familial ataxia ([@bib26]).

An intriguing case of SCA3 resembling MSA-C was reported recently ([@bib52]). Pathological changes met the consensus criteria for definite MSA ([@bib25]), including the presence of typical, α-synuclein containing GCIs, as well as neurodegenerative changes in the olivopontocerebellar, striatal, and pyramidal motor system. However, SCA3 expansions were not detected in a study of 80 Caucasian subjects with the clinical diagnosis of MSA indicating that SCA3 expansions are not a common cause of MSA ([@bib5]). Despite this observation, SCA3 gene variants might act as susceptibility factors for the development of MSA-C ([@bib52]).

SCA6 accounts for less than 10% of patients with sporadic adult-onset ataxia ([@bib1]), and it may rarely be confused with MSA because of associated levodopa-refractory parkinsonism ([@bib38]). A screening study in Japanese patients, however, did not reveal any individuals with trinucleotide repeat expansions in the SCA6 gene, indicating that SCA6 is not commonly associated with MSA ([@bib22]).

Factor and colleagues reported an ataxia patient with unstable CTA/CTG repeats in the SCA8 allele and a brain pathology consistent with MSA ([@bib42]) including ubiquitin- and α-synuclein-positive GCIs ([@bib19]). Repeat expansions in this gene were not observed in a Japanese study, suggesting that SCA8-related neurodegeneration is a rare genocopy of MSA ([@bib22]).

SCA17 is rare among the dominant ataxias ([@bib69]). Interestingly, pathogenic trinucleotide repeat expansions have been reported in several patients with SCA17-related neurodegeneration, presenting with MSA-like features such as ataxia, cerebellar atrophy, urinary incontinence, postural instability, and bradykinesia ([@bib40; @bib44]). However, a subsequent candidate gene screening study in Japanese MSA patients did not reveal pathogenic repeat expansions ([@bib22]).

The SCAs and other hereditary ataxias such as Friedreich\'s ataxia (FA) and fragile X-associated ataxia syndrome (FXTAS) can present as an apparently sporadic disorder. It has been shown that even in ataxia patients with a negative family history there is a 15%--20% chance of a mutation ([@bib1]). For instance, a study of 112 sporadic, late-onset ataxia patients found that 32 patients (29%) met the clinical criteria of possible (7%) or probable (22%) MSA. The Friedreich\'s ataxia mutation was found in 5 patients (4%), the SCA2 mutation in 1 (1%), the SCA3 mutation in 2 (2%), and the SCA6 mutation in 7 patients (6%) ([@bib1]).

Clinical overlap with MSA has also been reported for FXTAS because both disorders are characterized by mid-to late-onset cerebellar ataxia, levodopa-unresponsive parkinsonism, and autonomic features ([@bib37]). This similarity led to the assumption that a premutation in the fragile X mental retardation gene 1 (FMR1) could be a susceptibility gene mutation of MSA ([@bib97]). A study performed in Japanese MSA patients failed to support an association of FMR1 premutations and MSA ([@bib97]). Data from the European MSA study group also suggest that probable MSA is only rarely associated with FMR1 premutations and confusing FXTAS with MSA is very unlikely ([@bib37]).

In summary, genetic testing for SCA genes in MSA patients should not be considered as a routine clinical procedure, particularly because SCAs are generally of early-onset, slow in progression, and mainly present in patients with a positive family history. Nevertheless, presence of "red flags" raising doubts about a diagnosis of MSA should alert to the possibility of an inherited ataxia, in which case genetic testing for the above discussed genes can be initiated.

4. Risk loci in MSA {#sec4}
===================

4.1. SNCA {#sec4.1}
---------

The presence of α-synuclein immunoreactive GCIs in MSA places the disease amongst the broad category of synucleinopathies including PD as well as DLB ([@bib79]), and because of its fundamental role in MSA pathology, subsequent genetic approaches focused on the corresponding *SNCA* gene. Sequencing studies, gene dosage measurements, microsatellite testing, as well as a haplotype tagging approach failed to demonstrate a significant association of *SNCA* variants with MSA ([@bib45; @bib48; @bib58; @bib57]). This might have been because of the small sample size involved in these studies or because of common misdiagnosis in clinically ascertained cases.

In 2009, Scholz and colleagues demonstrated by a candidate single nucleotide polymorphism (SNP) association study that genetic variants within the *SNCA* locus are associated with an increased risk for developing MSA in Caucasian individuals (most significant single nucleotide polymorphism rs11931074: *p*-value under recessive model = 5.5 × 10^−12^, odds ratio for homozygous risk allele carriers = 6.2 \[95% confidence interval, 3.4--11.2\]) ([@bib70]). This result has been subsequently replicated in an independent set of autopsy-proven MSA cases ([@bib66]). Furthermore, genetic risk variants in *SNCA* have also been replicated by Al-Chalabi and colleagues ([@bib3]), although this study was not independent, as a large proportion of the investigated samples have been previously tested in the original study by Scholz and colleagues.

The identified risk variants are located in a haplotype block that extends from intron 4 to the 3′ untranslated region of the *SNCA* gene ([Fig. 1](#fig1){ref-type="fig"}) and are in strong linkage disequilibrium. It is of note, that the very same risk variants are also significantly associated with risk for PD ([@bib67; @bib75]), indicating shared pathogenic mechanisms between these 2 synucleinopathies.

In contrast, a more recent South Korean study reported higher frequencies of the previously identified risk variants in their control cohort and failed to identify an association with disease risk among clinically diagnosed MSA patients ([@bib100]). This observation suggests population heterogeneity at the *SNCA* locus similar to the heterogeneity described for the *MAPT*, *LRRK2* or *GBA* loci in PD.

It is unclear how the identified *SNCA* risk haplotype confers risk to developing MSA, in particular because pathogenic mutations in the *SNCA* coding sequence could not be identified ([@bib58; @bib57; @bib70]). Although gene dosage measurements in MSA patients did not reveal *SNCA* duplications or triplications ([@bib45]), modest changes in gene expression could still be possible. This notion is supported by the observation that duplication and triplication of *SNCA* in autosomal dominant PD families can lead to GCI-like inclusions and clinical features of MSA ([@bib21; @bib29; @bib76]). Furthermore, transgenic animals overexpressing α-synuclein under oligodendroglial promoters have demonstrated neuropathological findings resembling MSA ([@bib36; @bib73; @bib98]).

4.2. Candidate gene studies {#sec4.2}
---------------------------

Until recently, the study of molecular genetic mechanisms involved in sporadic diseases was limited to candidate gene approaches. While many candidate gene studies have provided crucial insights into the pathogenesis of human disease, it is critical that the interpretation of results from candidate gene studies is handled with caution. This is particularly true for much of the past candidate gene research in MSA where most studies have a low power due to small sample sizes or lack replication stages. [Table 1](#tbl1){ref-type="table"} provides a brief overview of candidate genes that have been tested to date. For the purpose of this review article, we will limit our discussion here to some of the major candidate genes.

*Parkin* and *PTEN-induced putative kinase 1* (*PINK1*) mutations are the most common causes of autosomal recessive early-onset PD ([@bib31; @bib56]). A comprehensive mutation screening study investigating the role of genetic variants in *parkin* and *PINK1* in pathology-proven MSA cases has been recently performed ([@bib10]). No clear pathogenic, homozygous mutations were identified, suggesting that genetic variants at these loci are not commonly associated with MSA ([@bib10]).

Genetic variability at the *MAPT* locus, coding for microtubule-associated protein tau, has been associated with a number of neurodegenerative diseases ([@bib2; @bib63; @bib93]). Studies testing for a potential effect of *MAPT* variants on MSA failed to identify significant associations ([@bib48; @bib70]). Along the same lines, mutations in the *LRRK2* and *GBA* genes, known to be risk factors for PD ([@bib46; @bib71; @bib74]), are not associated with MSA ([@bib59; @bib65; @bib71; @bib81]).

Recently it has been suggested that oxidative and nitrative stress are associated with the onset and progression of α-synucleinopathies. This theory is based on the observation of nitrated α-synuclein in GCIs and neuronal cytoplasmic inclusions in MSA brain samples as well as in Lewy bodies and Lewy neurites of PD and DLB brains ([@bib78]). Further, in vitro studies have revealed that nitric oxide and superoxide induce α-synuclein aggregation ([@bib18; @bib78]). Hence, genes involved in oxidative stress are interesting candidate genes for MSA. In a case-control study testing 8 candidate genes involved in oxidative stress significant associations were demonstrated for *SLC1A4*, *SQSTM1*, and finally *EIF4EBPI* ([@bib78]). Replication studies testing these putative risk variants still need to be performed to draw final conclusions on the relevance of these findings.

Microglial activation has been reported to parallel the neuronal multisystem degeneration in MSA ([@bib34]), suggesting neuroinflammation as a key pathogenic mechanism. Activation of microglia produces cytokines, such as interleukin-1α (IL-1α), IL-1β, IL-6, tumor necrosis factor-α (TNF-α), chemokines such as IL-8, as well as inflammatory markers such as intercellular-adhesion molecule-1 (ICAM-1), all of which are known to contribute to tissue injuries ([@bib96]). Thus, cytokine gene polymorphisms have been analyzed in several studies searching for genetic susceptibilities in MSA. Polymorphisms in IL-1α ([@bib17]), IL-1β ([@bib53]), IL-8 ([@bib33]), and ICAM-1 ([@bib33]) were reported to be associated with an increased risk of MSA. A similar finding was also demonstrated for a polymorphism of the α-1-antichymotrypsin gene ([@bib22]), as well as for a promoter region polymorphism in the tumor necrosis factor gene ([@bib55]). These studies are important, because they point toward a possible role of neuroinflammation in disease pathogenesis. Nevertheless, they were performed with a small number of patients and should be repeated in larger, independent cohorts.

Other risk factors such as mutations in the alcohol dehydrogenase genes *ADH1C* and *ADH7* have been analyzed in MSA patients. The *ADHC1* G78X mutation was shown to be associated with MSA in the British, but not in the German population ([@bib68]), whereas no significant associations were detected in *ADH7* ([@bib39]).

One of the latest discussions in neurological diseases center on the question of whether neurodegeneration can be caused in a cell-autonomous manner via independent formation of abnormal protein aggregates in affected brain cells, or whether propagation of protein misfolding occurs through mechanisms similar to those underlying prion diseases ([@bib27]). An intriguing case of MSA followed by sporadic prion disease has been published ([@bib72]). Genetic analysis of this patient did not reveal any mutations in the prion protein gene (*PRNP*), but it was noted that the proband was MM homozygous for the common M129V polymorphism ([@bib72]). A case-control study was initiated to investigate a possible connection between the M129V polymorphism and MSA ([@bib72]). The study revealed that the homozygotes are associated with an increased risk of MSA and earlier disease onset compared with PD subjects; however no association was observed when genotype frequencies were compared with matched controls.

Cardinal features of MSA include symptoms of progressive autonomic failure ([@bib24]). Internal body functions are maintained and regulated by the autonomic nervous system (ANS) with norepinephrine (NE) as its major neurotransmitter. Hence deficiency in NE, caused by mutations in the dopamine-β-hydroxylase (*DBH*) gene, may be associated with disorders of autonomic function ([@bib16]). In an association study, patients with orthostatic intolerance, pure autonomic failure, MSA, and controls were genotyped for 7 mutations in the *DBH* gene. No mutations were found, suggesting that the major pathogenic mechanisms involved in NE deficiency and other autonomic disorders are fundamentally different ([@bib16]).

Myotonic dystrophy type 2 (*DM2*), a slowly progressive multisystem disorder, has been recently associated with Parkinsonism ([@bib4]). Lim and colleagues reported a case of clinically probable MSA-P, who developed muscle weakness and genetic testing confirmed 1 abnormal and 1 normal allele of the *ZNF9* gene ([@bib43]). This is so far the only report on a MSA patient with abnormalities in the *ZNF9* gene.

Likewise, apolipoprotein E (APOE), associated with Alzheimer\'s disease (AD) and DLB, is not considered to be a player in MSA pathogenesis and does not contribute to an earlier disease onset ([@bib13; @bib48; @bib47]). No disease association has furthermore been detected for genetic variants of the progranulin (*PRGN*) gene ([@bib99]).

5. General considerations and limitations of current studies {#sec5}
============================================================

Genetic investigation in an apparently sporadic, rare disease comes with a number of challenges. First, large collections of DNA and tissue samples are required for sufficiently powered studies. This hurdle can be overcome by depositing samples to brain and DNA banks. Second, the availability of pathology-proven samples is crucial due to the high misdiagnosis rate in clinically ascertained cases. These samples are particularly important to validate potential risk variants in replication studies. Third, linkage studies, the standard genetic tool for disease gene identification, are not feasible in sporadic cases. However, recent advancements in neurogenomics have introduced genome-wide association studies and next-generation sequencing techniques as promising new tools for studying the genetic underpinnings of sporadic disease.

6. Conclusions {#sec6}
==============

Within the last 2 decades, extensive studies investigating the role of genetic players in the pathogenesis of MSA have established variants in the *SNCA* locus as the only confirmed risk factor in the pathogenesis of MSA. Although other candidate genes have been implicated, independent replication studies are still necessary to confirm or refute these observations. To date, no protein-changing Mendelian gene mutations have been identified in rare families of MSA. More advanced genetic tools such as genome-wide association studies and next-generation sequencing are likely to unfold the mysterious nature of the beast ([@bib64]).
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###### 

Candidate gene studies in MSA

  Positive findings                                                                        Negative findings
  ---------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Familial aggregation**                                                                 
   ([@bib30; @bib50; @bib77; @bib86; @bib92; @bib94; @bib95])                              ([@bib85])
                                                                                           
  **Ataxia genes**                                                                         
   SCA3 ([@bib52]) SCA6 ([@bib38]) SCA8 ([@bib19]) SCA17 ([@bib40; @bib44]) FA ([@bib1])   SCA1--3, 6--8, 12,17 ([@bib5; @bib7; @bib8; @bib9]; [@bib14]; [@bib26]) FMR1 ([@bib37; @bib97])
                                                                                           
  **PD genes**                                                                             
   SNCA ([@bib3; @bib66; @bib70])                                                          SNCA ([@bib45; @bib48; @bib58; @bib57])Synphilin (Brooks et al., 2009; [@bib48])PINK1 (Brooks et al., 2009)Parkin (Brooks et al., 2009)LRRK2 ([@bib15]; [@bib59; @bib65; @bib81])GBA ([@bib28; @bib71])MAPT ([@bib48; @bib70])CYP2D6 ([@bib6; @bib35];[@bib61])CYP1A ([@bib51])GMST1 ([@bib51])NAT2 ([@bib51])DAT1 ([@bib51])
                                                                                           
  **Genes associated with oxidative stress**                                               
   SLC1A4, SQSTM1, EIF4EBPI ([@bib78])                                                     CHOP, ATF3, ATF4, CEBPB, CARS ([@bib78])
                                                                                           
  **Genes associated with neuroinflammation**                                              
   IL-1α ([@bib17])                                                                        IL-1RA ([@bib53])
   IL-1β ([@bib53])                                                                        IL-6 ([@bib55])
   TNF ([@bib55])                                                                          IL-10 ([@bib55])
   IL-8/ICAM-1 ([@bib33])                                                                  TGF-β1 ([@bib55])
   ACT-A/A ([@bib22])                                                                      TNF ([@bib33])
                                                                                           IGF1 ([@bib5])
                                                                                           
  **Other genetic risk factors**                                                           
   ADH1C ([@bib68])                                                                        ADH7 ([@bib12])
  PRNP ([@bib72])                                                                          
  UCHL-1 ([@bib32])                                                                        
  BDNF ([@bib54])                                                                          
  CNTF ([@bib5])                                                                           
  IGF1 ([@bib5])                                                                           
  HLA ([@bib5])                                                                            
  hiGIRK ([@bib5])                                                                         
  DBH ([@bib16])                                                                           
  DM2 ([@bib43])                                                                           
  mtDNA ([@bib101])                                                                        
  APOE ([@bib48])                                                                          
  PGRN ([@bib99])                                                                          

Key: ACT-A/A, α-1-antichymotrypsin; ADH, alcohol dehydrogenase; APOE, apolipoprotein E; ATF3, activating transcription factor 3; ATF4, activating transcription factor 4; BDNF, brain-derived neurotrophic factor; CARS, cysteinyl t-RNA synthetase; CEBPB, CCAAT/enhancer-binding protein-β; CHOP, CCAAT/enhancer-binding protein homologous protein; CNTF, ciliary neurotrophic factor; CYP1A1, cytochrome P450 1A1; CYP2D6, cytochrome P450 2D6; DAT1, dopamine transporter 1; DBH, dopamine-β-hydroxylase; DM2, myotonic dystrophy 2; EIF4EBP, eukaryotic translation initiation factor 4E-binding protein; FMR1, fragile X mental retardation 1; GSTM1, glutathione S-transferase M1; HLA, human leukocyte antigen; ICAM-1, intercellular adhesion molecule 1; IGF-1, insulin-like growth factor 1; IL, interleukin; LRRK2, leucine-rich repeat kinase 2; MAPT, microtubule-associated protein tau; MSA, multiple system atrophy; NAT2, N-acetyltransferase 2; PRGN, progranulin; SCA, spinocerebellar ataxia; SLC1A4, solute carrier family 1A4; SNCA, α-synuclein; SQSTM1, sequestosome 1; TGF-β1, transforming growth factor-β1; TNF-α, tumor necrosis factor-α; UCH-L1, ubiquitin carboxyl-terminal esterase L1.
